Skip to main content

Advertisement

Articles

Page 121 of 121

  1. Large scale clinical trials demonstrate significant reductions in cardiovascular event rates with statin therapy. The observed benefit of statin therapy, however, may be larger in these trials than that expect...

    Authors: Gavin J Blake and Paul M Ridker

    Citation: Trials 2000 1:161

    Content type: Review

    Published on:

  2. 1. To assess the long-term effectiveness of a comprehensive cardiac rehabilitation programme on quality of life and survival in patients with a large spectrum of cardiovascular diseases (myocardial infarction,...

    Authors: Cornel Pater, Carl Ditlef Jacobsen, Arnfinn Rollag, Leiv Sandvik, Jan Erikssen and Else Karin Kogstad

    Citation: Trials 2000 1:177

    Content type: Research

    Published on:

  3. Chronic heart failure (CHF) is a common condition with a poor prognosis. It is associated with poor exercise tolerance and debilitating symptoms. These symptoms appear to be associated with pathophysiological ...

    Authors: Andrew JS Coats

    Citation: Trials 2000 1:155

    Content type: Review

    Published on:

  4. Gene therapy using in vivo recombinant adenovirus-mediated gene transfer is an effective technique that offers great potential to improve existing drug treatments for the complex cardiovascular diseases of heart ...

    Authors: Andrea D Eckhart and Walter J Koch

    Citation: Trials 2000 1:131

    Content type: Commentary

    Published on:

  5. Lipid disorders are associated with atherosclerotic vascular disease, and therapy is associated with a substantial reduction in cardiovascular events. Current approaches to the treatment of lipid disorders are...

    Authors: Masa-aki Kawashiri and Daniel J Rader

    Citation: Trials 2000 1:120

    Content type: Review

    Published on:

  6. Despite the major advances in medical drug therapy, heart failure remains a syndrome associated with high mortality and morbidity. Biventricular or left ventricular (LV) short atrioventricular (AV) delay pacin...

    Authors: Jayne A Morris-Thurgood and Michael P Frenneaux

    Citation: Trials 2000 1:107

    Content type: Review

    Published on:

  7. Surrogate outcomes are frequently used in cardiovascular disease research. A concern is that changes in surrogate markers may not reflect changes in disease outcomes. Two recent clinical trials (Heart and Estr...

    Authors: Ralph B D'Agostino Jr

    Citation: Trials 2000 1:76

    Content type: Commentary

    Published on:

  8. Surrogate end-points of cardiovascular disease can provide useful information in cross-sectional, prospective and interventional studies. They provide information on association with risk factors, natural hist...

    Authors: Jonathan Valabhji and Robert S Elkeles

    Citation: Trials 2000 1:72

    Content type: Commentary

    Published on:

  9. Whether it matters how pressure is lowered has been debated since antihypertensive drugs proved to prevent cardiovascular events. However, in clinical trials, while the stroke benefit predicted by a given diff...

    Authors: Michael H Alderman

    Citation: Trials 2000 1:69

    Content type: Commentary

    Published on:

  10. Direct myocardial cell protection in patients with unstable angina or evolving myocardial infarction (MI) could prevent cell necrosis or reduce its extent, and minimize the risk of MI and death associated with...

    Authors: Pierre Theroux, Bernard R Chaitman, Leif Erhardt, Andreas Jessel, Thomas Meinertz, Wolf-Ulrich Nickel, John S Schroeder, Gianni Tognoni, Harvey White and James T Willerson

    Citation: Trials 2000 1:59

    Content type: Research

    Published on:

  11. The results of recent randomized trials to test the influence of antioxidants on coronary-event rates and prognosis in patients with coronary-artery disease were disappointing. In none of these studies did the...

    Authors: Ascan Warnholtz and Thomas Münzel

    Citation: Trials 2000 1:38

    Content type: Commentary

    Published on:

  12. The present review assesses the data on long-term outcome after coronary stenting. Histological, angiographical and intravascular imaging data have shown that the insertion of stents constitutes only a transie...

    Authors: Adnan Kastrati, Donald Hall and Albert Schömig

    Citation: Trials 2000 1:48

    Content type: Review

    Published on:

  13. Although the TIMI (Thrombolysis In Myocardial Infarction) flow grade classification scheme is widely used to assess angiographic outcomes, it is limited by poor reproducibility and its categoric nature. The co...

    Authors: Mark A Appleby, Andrew D Michaels, Michael Chen and C Gibson Michael

    Citation: Trials 2000 1:31

    Content type: Commentary

    Published on:

  14. This symposium provided a useful forum for the discussion of issues relating to the design and conduct of clinical trials. There is a need for greater awareness of the complexity of modern day trials, in which...

    Authors: Rachel N Johnatty

    Citation: Trials 2000 1:55

    Content type: Meeting report

    Published on:

  15. Noninferiority trials are intended to show that the effect of a new treatment is not worse than that of an active control by more than a specified margin. These trials have a number of inherent weaknesses that...

    Authors: Steven M Snapinn

    Citation: Trials 2000 1:19

    Content type: Commentary

    Published on:

  16. The prognosis of patients who present with non-ST segment elevation acute coronary syndromes (ACS) is guarded. These patients can be risk-stratified on the basis of symptom complex, electrocardiographic ST seg...

    Authors: Dean J Kereiakes

    Citation: Trials 2000 1:9

    Content type: Commentary

    Published on:

Annual Journal Metrics

Advertisement